Appleton Partners Inc. MA Invests $7.01 Million in Solventum Corporation $SOLV

Appleton Partners Inc. MA purchased a new stake in Solventum Corporation (NYSE:SOLV) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 88,446 shares of the company’s stock, valued at approximately $7,008,000. Appleton Partners Inc. MA owned 0.05% of Solventum at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Hilltop National Bank boosted its position in shares of Solventum by 71.3% during the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after purchasing an additional 129 shares in the last quarter. Allworth Financial LP boosted its holdings in Solventum by 2.8% during the third quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock worth $350,000 after buying an additional 129 shares in the last quarter. CIBC Private Wealth Group LLC boosted its holdings in Solventum by 0.5% during the third quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock worth $1,804,000 after buying an additional 134 shares in the last quarter. BOKF NA grew its position in Solventum by 6.9% during the third quarter. BOKF NA now owns 2,193 shares of the company’s stock worth $160,000 after buying an additional 141 shares during the period. Finally, CHICAGO TRUST Co NA increased its holdings in Solventum by 3.0% in the third quarter. CHICAGO TRUST Co NA now owns 5,188 shares of the company’s stock valued at $379,000 after buying an additional 150 shares in the last quarter.

Solventum Stock Down 0.1%

Shares of NYSE SOLV opened at $65.74 on Tuesday. The firm’s 50-day moving average is $74.32 and its two-hundred day moving average is $75.78. The company has a market capitalization of $11.41 billion, a PE ratio of 7.41, a price-to-earnings-growth ratio of 1.08 and a beta of 0.40. Solventum Corporation has a 12-month low of $60.70 and a 12-month high of $88.20. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.23 and a quick ratio of 0.89.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Thursday, February 26th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The business had revenue of $2 billion during the quarter, compared to analysts’ expectations of $1.96 billion. During the same period last year, the company posted $1.41 EPS. The company’s revenue was down 3.7% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Equities analysts anticipate that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on SOLV shares. Wells Fargo & Company upgraded shares of Solventum to a “hold” rating in a research report on Wednesday, March 18th. BTIG Research restated a “buy” rating and issued a $100.00 price target on shares of Solventum in a report on Friday, February 27th. Wall Street Zen downgraded Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Stifel Nicolaus lifted their price objective on Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a research report on Tuesday, January 27th. Seven analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Solventum currently has an average rating of “Moderate Buy” and a consensus price target of $93.70.

Insiders Place Their Bets

In related news, Director Amy Mcbride Wendell purchased 1,475 shares of the company’s stock in a transaction on Tuesday, March 10th. The stock was bought at an average price of $68.03 per share, with a total value of $100,344.25. Following the completion of the transaction, the director owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. This represents a 41.39% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.05% of the company’s stock.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.